新型咪唑类药物兰诺康唑和卢立康唑对一系列唑类耐药和敏感烟曲霉菌株的强效活性
Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains.
作者信息
Abastabar Mahdi, Rahimi Nooshin, Meis Jacques F, Aslani Narges, Khodavaisy Sadegh, Nabili Mojtaba, Rezaei-Matehkolaei Ali, Makimura Koichi, Badali Hamid
机构信息
Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
出版信息
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6916-6919. doi: 10.1128/AAC.01193-16. Print 2016 Nov.
Abstract
A collection of azole-susceptible (n = 141) and azole-resistant (n = 27) Aspergillus fumigatus isolates was tested against seven antifungal drugs, including the new imidazoles lanoconazole and luliconazole. The luliconazole and lanoconazole MIC values for the azole-susceptible strains were 0.001 μg/ml and 0.008 μg/ml, and those for the azole-resistant strains were 0.016 μg/ml and 0.032 μg/ml.
摘要
对一组烟曲霉分离株进行了测试，其中包括141株对唑类敏感的菌株和27株对唑类耐药的菌株，测试针对七种抗真菌药物，包括新型咪唑类药物兰诺康唑和卢立康唑。对唑类敏感菌株的卢立康唑和兰诺康唑的最低抑菌浓度（MIC）值分别为0.001μg/ml和0.008μg/ml，对唑类耐药菌株的MIC值分别为0.016μg/ml和0.032μg/ml。
相似文献
1
Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6916-6919. doi: 10.1128/AAC.01193-16. Print 2016 Nov.
2
In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
J Antimicrob Chemother. 2017 Sep 1;72(9):2548-2552. doi: 10.1093/jac/dkx177.
3
Epidemiology and Molecular Characterizations of Azole Resistance in Clinical and Environmental Aspergillus fumigatus Isolates from China.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5878-84. doi: 10.1128/AAC.01005-16. Print 2016 Oct.
4
Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.
J Antimicrob Chemother. 2010 Oct;65(10):2116-8. doi: 10.1093/jac/dkq279. Epub 2010 Aug 20.
5
Azole-resistant Aspergillus fumigatus in Denmark: a laboratory-based study on resistance mechanisms and genotypes.
Clin Microbiol Infect. 2016 Jun;22(6):570.e1-9. doi: 10.1016/j.cmi.2016.04.001. Epub 2016 Apr 16.
6
Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA.
J Antimicrob Chemother. 2017 Sep 1;72(9):2443-2446. doi: 10.1093/jac/dkx168.
7
Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania.
J Antimicrob Chemother. 2014 Nov;69(11):2979-83. doi: 10.1093/jac/dku259. Epub 2014 Jul 7.
8
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus.
Emerg Infect Dis. 2015 Jun;21(6):1041-4. doi: 10.3201/eid2106.140717.
9
[In vitro Antifungal Activity of Luliconazole against Trichophyton spp].
Med Mycol J. 2016;57(1):J1-6. doi: 10.3314/mmj.57.J1.
10
Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China.
Antimicrob Agents Chemother. 2015 Jul;59(7):4321-5. doi: 10.1128/AAC.00003-15. Epub 2015 Apr 20.
引用本文的文献
1
Molecular epidemiology, diversity, and antifungal susceptibility profiles of clinical and environmental mucorales: a five-year multicenter study in Iran (2018-2023).
BMC Infect Dis. 2025 Jul 1;25(1):849. doi: 10.1186/s12879-025-11189-7.
2
Antifungal Efficacy of Luliconazole-Loaded Nanostructured Lipid-Carrier Gel in an Animal Model of Dermatophytosis.
J Fungi (Basel). 2025 Apr 19;11(4):324. doi: 10.3390/jof11040324.
3
Luliconazole-loaded nanostructured lipid carrier: formulation, characterization, and in vitro antifungal evaluation against a panel of resistant fungal strains.
Sci Rep. 2024 Dec 28;14(1):30708. doi: 10.1038/s41598-024-79225-1.
4
and Effect of the Imidazole Luliconazole against and spp.
Microbiol Spectr. 2023 Jun 15;11(3):e0513022. doi: 10.1128/spectrum.05130-22. Epub 2023 Apr 5.
5
Keratitis in Taiwan: Molecular Identification, Antifungal Susceptibilities, and Clinical Features.
J Fungi (Basel). 2022 May 3;8(5):476. doi: 10.3390/jof8050476.
6
In Vitro and In Vivo Activity of Luliconazole (NND-502) against Planktonic Cells and Biofilms of Azole Resistant .
J Fungi (Basel). 2022 Mar 28;8(4):350. doi: 10.3390/jof8040350.
7
Genotypic diversity of Iranian Cryptococcus neoformans using multilocus sequence typing (MLST) and susceptibility to antifungals.
Mol Biol Rep. 2021 May;48(5):4201-4208. doi: 10.1007/s11033-021-06433-7. Epub 2021 May 31.
8
Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.
Mycopathologia. 2021 May;186(2):245-257. doi: 10.1007/s11046-021-00537-1. Epub 2021 Mar 15.
9
Molecular identification, biofilm formation and antifungal susceptibility of Rhodotorula spp.
Mol Biol Rep. 2020 Nov;47(11):8903-8909. doi: 10.1007/s11033-020-05942-1. Epub 2020 Nov 1.
10
The high efficacy of luliconazole against environmental and otomycosis strains.
Iran J Microbiol. 2020 Apr;12(2):170-176.
本文引用的文献
1
Clinical implications of globally emerging azole resistance in Aspergillus fumigatus.
Philos Trans R Soc Lond B Biol Sci. 2016 Dec 5;371(1709). doi: 10.1098/rstb.2015.0460.
2
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29.
3
In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates.
Med Mycol. 2016 Oct 1;54(7):757-63. doi: 10.1093/mmy/myw016. Epub 2016 Apr 26.
4
High prevalence of clinical and environmental triazole-resistant Aspergillus fumigatus in Iran: is it a challenging issue?
J Med Microbiol. 2016 Jun;65(6):468-475. doi: 10.1099/jmm.0.000255. Epub 2016 Mar 23.
5
A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections.
Infect Drug Resist. 2016 Jan 18;9:1-6. doi: 10.2147/IDR.S61998. eCollection 2016.
6
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.
7
Diagnosis and management of aspergillosis in the Netherlands: a national survey.
Mycoses. 2016 Feb;59(2):101-7. doi: 10.1111/myc.12440. Epub 2015 Dec 9.
8
Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?
Clin Infect Dis. 2016 Feb 1;62(3):362-8. doi: 10.1093/cid/civ885. Epub 2015 Oct 20.
9
Luliconazole for the treatment of fungal infections: an evidence-based review.
Core Evid. 2014 Sep 24;9:113-24. doi: 10.2147/CE.S49629. eCollection 2014.
10
Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.
Antimicrob Agents Chemother. 2014 Jun;58(6):3553-5. doi: 10.1128/AAC.02706-13. Epub 2014 Apr 7.
Zotero 插件